Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/842"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label |
"evidence_1035"
|
| rdf:type | |
| ?:Evidence_dose | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:Evidence_value | |
| ?:content |
"route of administration: oral
study duration: "Methods Single and multiple doses of ziprasidone were given orally (as two divided daily doses), at fixed dosages of 10 and 40 mg/day, and using titrated regimens of 40 +/- 80 and 40 +/-120 mg/day, for 14 days. All dosages were taken immediately after food.
population: 39 healthy, non-smoking, males. None were tested for known CYP450 phenotypes. "In this double-blind, parallel-group study, subjects were randomised to receive placebo or one of four doses of ziprasidone"
ages: 18 - 49
C_max @ 120mg/day: 139.4ng/mL
139.4ng/mL x 1g/10^9ng x 1000mL/1L = 0.0001394g/L"
|
| dc:creator | |
| dc:date |
"06/19/2009 18:44:50"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ ziprasidone_maximum_concentration_continuous_value, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1035 }